Skip to main content
SpringerLink
Log in

Monoclonal Gammopathy of Undetermined Significance

  • Chapter
  • First Online:
Neoplastic Diseases of the Blood

  • 2200 Accesses

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell disorder present in 2.4% of the general population over the age of 50 years. MGUS is defined as the presence of a monoclonal protein <3.0 g/dL, <10% clonal plasma cells in the bone marrow, and absence of plasma cell-related end-organ damage. Multiple myeloma is consistently preceded by MGUS but the majority of patients with MGUS will never develop malignant disease. There are three major types of MGUS: non-IgM MGUS, IgM MGUS, and light-chain MGUS which typically progress to multiple myeloma, Waldenström’s macroglobulinemia, and light-chain multiple myeloma, respectively. The etiology of MGUS is largely unknown but male gender, ethnicity, previous autoimmune disease, and exposure to certain pesticides have been associated with increased risk of developing MGUS. Patients with MGUS are in the majority of cases asymptomatic but increased risks of comorbidities such as thrombosis, infection, and skeletal fractures have been observed.

The risk of progression from MGUS to multiple myeloma and other lymphoproliferative disorders is approximately 0.5–1% per year and persists throughout follow-up why these patients need to be continuously monitored. The risk of progression can be predicted using different risk scores largely based on biomarkers: M-protein characteristics, uninvolved immunoglobulins and free light chains, as well as aberrant plasma cells in the bone marrow. Nevertheless, there is a need for development of molecular markers to better predict individual risk of progression. This chapter discusses disease definition, risk of progression, and clinical implications in patients with MGUS.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Waldenstrom J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 1960;56:211–31.

    PubMed  Google Scholar 

  2. Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 1978;64(5):814–26.

    Article  CAS  PubMed  Google Scholar 

  3. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.

    Article  PubMed  Google Scholar 

  4. Kristinsson SY, Bjorkholm M, Landgren O. Survival in monoclonal gammopathy of undetermined significance and Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013;13(2):187–90.

    Article  PubMed  Google Scholar 

  5. Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014;28(7):1537–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Landgren O, Shim YK, Michalek J, Costello R, Burton D, Ketchum N, et al. Agent Orange exposure and monoclonal Gammopathy of undetermined significance: an Operation Ranch Hand veteran cohort study. JAMA Oncol. 2015;1(8):1061–8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123(3):338–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586–92.

    Article  CAS  PubMed  Google Scholar 

  9. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121–7.

    Article  CAS  PubMed  Google Scholar 

  11. Kyle RA, Therneau TM, Dispenzieri A, Kumar S, Benson JT, Larson DR, et al. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013;13(2):184–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367(9):826–33.

    Article  CAS  PubMed  Google Scholar 

  13. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med. 2012;367(23):2255–6. author reply 6–7

    Article  CAS  PubMed  Google Scholar 

  14. Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13):2522–8.

    Article  CAS  PubMed  Google Scholar 

  15. Schuster SR, Rajkumar SV, Dispenzieri A, Morice W, Aspitia AM, Ansell S, et al. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom’s macroglobulinemia. Am J Hematol. 2010;85(11):853–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375(9727):1721–8.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Landgren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res. 2011;17(6):1243–52.

    Article  PubMed  Google Scholar 

  18. Hutchison CA, Landgren O. Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. Clin Chem. 2011;57(10):1387–9.

    Article  CAS  PubMed  Google Scholar 

  19. Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007;82(12):1468–73.

    Article  PubMed  Google Scholar 

  20. Eisele L, Durig J, Huttmann A, Duhrsen U, Assert R, Bokhof B, et al. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol. 2012;91(2):243–8.

    Article  CAS  PubMed  Google Scholar 

  21. Kristinsson SY, Bjorkholm M, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, et al. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer. 2009;125(9):2147–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Greenberg AJ, Rajkumar SV, Larson DR, Dispenzieri A, Therneau TM, Colby CL, et al. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma. Br J Haematol. 2012;157(4):472–5.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Greenberg AJ, Rajkumar SV, Vachon CM. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood. 2012;119(23):5359–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Morgan GJ, Johnson DC, Weinhold N, Goldschmidt H, Landgren O, Lynch HT, et al. Inherited genetic susceptibility to multiple myeloma. Leukemia. 2014;28(3):518–24.

    Article  CAS  PubMed  Google Scholar 

  25. Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood. 2009;113(25):6386–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lindqvist EK, Goldin LR, Landgren O, Blimark C, Mellqvist UH, Turesson I, et al. Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood. 2011;118(24):6284–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564–9.

    Article  PubMed  Google Scholar 

  29. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582–90.

    Article  CAS  PubMed  Google Scholar 

  30. Perez-Persona E, Mateo G, Garcia-Sanz R, Mateos MV, de Las Heras N, de Coca AG, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol. 2010;148(1):110–4.

    Article  PubMed  Google Scholar 

  31. Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ 3rd, et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia. 2013;27(1):208–12.

    Article  CAS  PubMed  Google Scholar 

  32. Rosinol L, Cibeira MT, Montoto S, Rozman M, Esteve J, Filella X, et al. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc. 2007;82(4):428–34.

    Article  CAS  PubMed  Google Scholar 

  33. Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood. 2014;123(1):78–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol. 2005;23(24):5668–74.

    Article  PubMed  Google Scholar 

  35. Papanikolaou X, Rosenthal A, Dhodapkar M, Epstein J, Khan R, van Rhee F, et al. Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120). Blood Cancer J. 2016;6:e410.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. van de Donk NW, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Int J Lab Hematol. 2016;38(Suppl 1):110–22.

    Article  PubMed  Google Scholar 

  37. Owen RG, Pratt G, Auer RL, Flatley R, Kyriakou C, Lunn MP, et al. Guidelines on the diagnosis and management of Waldenstrom macroglobulinaemia. Br J Haematol. 2014;165(3):316–33.

    Article  PubMed  Google Scholar 

  38. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100(4):1417–24.

    CAS  PubMed  Google Scholar 

  39. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational Spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911–20.

    Article  CAS  PubMed  Google Scholar 

  43. Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016. pii: blood-2016-09-692954 [Epub ahead of print].

    Google Scholar 

  44. Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Bjorkholm M, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9):3582–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Kristinsson SY, Pfeiffer RM, Bjorkholm M, Goldin LR, Schulman S, Blimark C, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115(24):4991–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Blimark C, Mellqvist UH, et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood. 2010;116(15):2651–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Ng AC, Khosla S, Charatcharoenwitthaya N, Kumar SK, Achenbach SJ, Holets MF, et al. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1alpha levels in patients with MGUS. Blood. 2011;118(25):6529–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Lindqvist EK, Lund SH, Costello R, Burton D, Korde NS, Mailankody S, et al. No risk of arterial or venous thrombosis in monoclonal gammopathy of undetermined significance: results from a population-based study. Blood. 2015;126(23):4252.

    Google Scholar 

  49. Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, Mailankody S, et al. Monoclonal Gammopathy of undetermined significance (Mgus) is associated with a 30% increased risk of dying at 8 years of follow-up: results from a screened cross-sectional population-based study. Haematologica. 2014;99:115.

    Article  Google Scholar 

  50. Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87(4):698–711.

    Article  CAS  PubMed  Google Scholar 

  51. Mateos MV, Landgren O. MGUS and smoldering multiple myeloma: diagnosis and epidemiology. Cancer Treat Res. 2016;169:3–12.

    Article  CAS  PubMed  Google Scholar 

  52. van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 2014;99(6):984–96.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Sigurdardottir E, Turesson I, Lund S, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 2015;1(2):168–74.

    Article  PubMed  Google Scholar 

  54. Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin Lymphoma Myeloma Leuk. 2015;15(3):177–186.e4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA

    Malin Hultcrantz M.D., Ph.D. & Ola Landgren M.D., Ph.D.

Authors
  1. Malin Hultcrantz M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ola Landgren M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Malin Hultcrantz M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Cancer Research Foundation, Chappaqua, New York, USA

    Peter H. Wiernik

  2. Cancer Research Foundation, Chappaqua, New York, USA

    Janice P. Dutcher

  3. Department of Hematology, Mayo Clinic Department of Hematology, Rochester, Minnesota, USA

    Morie A. Gertz

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Cite this chapter

Hultcrantz, M., Landgren, O. (2018). Monoclonal Gammopathy of Undetermined Significance. In: Wiernik, P., Dutcher, J., Gertz, M. (eds) Neoplastic Diseases of the Blood. Springer, Cham. https://doi.org/10.1007/978-3-319-64263-5_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64263-5_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64262-8

  • Online ISBN: 978-3-319-64263-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation